Neuralstem Inc has a peer-reviewed paper published talking about the improvements of rat brain after ischemic-stroke with the use of NSI566 neural stemcells. Neuralstem is currently conducting a Phase II NSI-566 clinical trial in amyotrophic lateral sclerosis (ALS or Lou Gehrig’s disease) in three U.S. sites, as well as a Phase I/II to treat post-stroke motor deficit in China, through its wholly-owned subsidiary, Neuralstem China. The company also has been approved by the FDA to commence a trial with the same cells to treat chronic spinal cord injury. This is only one of the great research projects going on in the biotech hub Rockville Maryland.. where I will be for the next year! I can’t wait.

Advertisements